Brad McGregor, MD
Brad McGregor, MD, is the Director of Clinical Research for the Lank Center of Genitourinary Oncology serving as a Medical Oncologist specializing in genitourinary malignancies at the Dana-Farber Cancer Institute.
Articles by Brad McGregor, MD
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
Dr. McGregor explains the safety, efficacy, and subgroup analysis from ARC-20 in patients with previously treated ccRCC.
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
The panel shared their excitement for the road ahead in kidney cancer.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.